KRYS

NASDAQ 已收盘

Krystal Biotech

315.82 USD
▲+0.48+0.15%
盘后 310.34 0.00%
2026-11-19
市值
$9.33B
市盈率
42.78
EPS
7.36
股息率
—
52 周区间
203.18 – 382.54
成交量
295.87K
Beta
0.65
目标价
388.22
52W 低 203.1852W 高 382.54
价格走势

公司简介

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...